Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.93M Sell
12,035
-340
-3% -$94.2K 0.08% 90
2025
Q4
$4.33M Buy
12,375
+9,521
+334% +$3.24M 0.12% 77
2025
Q3
$1.01M Sell
2,854
-63
-2% -$22.6K 0.03% 144
2025
Q2
$1.13M Buy
2,917
+552
+23% +$213K 0.04% 140
2025
Q1
$907K Sell
2,365
-85
-3% -$36.5K 0.03% 145
2024
Q4
$1.09M Buy
2,450
+134
+6% +$66.3K 0.04% 135
2024
Q3
$1.2M Sell
2,316
-163
-7% -$89.4K 0.05% 134
2024
Q2
$1.38M Sell
2,479
-232
-9% -$112K 0.06% 112
2024
Q1
$1.37M Buy
2,711
+179
+7% +$103K 0.06% 124
2023
Q4
$1.51M Buy
2,532
+64
+3% +$36.9K 0.07% 110
2023
Q3
$1.26M Buy
2,468
+113
+5% +$59.3K 0.06% 115
2023
Q2
$1.15M Hold
2,355
0.06% 123
2023
Q1
$908K Sell
2,355
-2
-0.1% -$711 0.05% 138
2022
Q4
$793K Sell
2,357
-477
-17% -$153K 0.04% 145
2022
Q3
$780K Buy
2,834
+36
+1% +$13.6K 0.04% 137
2022
Q2
$1.02M Buy
2,798
+337
+14% +$137K 0.05% 121
2022
Q1
$1.12M Buy
2,461
+34
+1% +$16.4K 0.06% 125
2021
Q4
$1.38M Buy
2,427
+90
+4% +$56.3K 0.07% 113
2021
Q3
$1.35M Hold
2,337
0.08% 98
2021
Q2
$1.37M Sell
2,337
-90
-4% -$46.4K 0.08% 95
2021
Q1
$1.15M Sell
2,427
-29
-1% -$13.6K 0.07% 93
2020
Q4
$1.23M Buy
2,456
+11
+0.4% +$5.31K 0.08% 86
2020
Q3
$1.2M Buy
2,445
+2
+0.1% +$930 0.09% 91
2020
Q2
$1.06M Buy
2,443
+79
+3% +$29.3K 0.1% 77
2020
Q1
$752K Sell
2,364
-100
-4% -$34.2K 0.07% 95
2019
Q4
$813K Sell
2,464
-153
-6% -$45K 0.08% 105
2019
Q3
$722K Sell
2,617
-309
-11% -$90.2K 0.06% 121
2019
Q2
$862K Sell
2,926
-67
-2% -$18.6K 0.07% 120
2019
Q1
$796K Sell
2,993
-265
-8% -$66.8K 0.07% 129
2018
Q4
$738K Buy
3,258
+829
+34% +$200K 0.06% 123
2018
Q3
$656K Sell
2,429
-8,586
-78% -$2.21M 0.06% 136
2018
Q2
$2.69M Buy
11,015
+8,616
+359% +$2.04M 0.23% 68
2018
Q1
$518K Buy
+2,399
New +$488K 0.05% 151
2017
Q4
Sell
-2,554
Closed -$381K 86
2017
Q3
$381K Hold
2,554
0.03% 150
2017
Q2
$361K Sell
2,554
-7,396
-74% -$1.01M 0.03% 160
2017
Q1
$1.29M Buy
+9,950
New +$1.17M 0.11% 103

Other funds holding ADBE

Aspiriant LLC's ADBE Position: Q1 2026 in Review

Aspiriant LLC reduced its Adobe (ADBE) stake by 2.7% in Q1 2026, selling an estimated $94.2K and leaving 12,035 shares worth $2.93M. The position accounts for 0.08% of the portfolio, ranked #90.

Aspiriant LLC first reported a position in ADBE in Q1 2017 and has held it in 36 quarters since. The position peaked at $4.33M in Q4 2025. 2,178 funds tracked by Wall St. Rank hold ADBE as of Q1 2026.

  • Aspiriant LLC held 12,035 shares of Adobe worth $2.93M as of Q1 2026.
  • Aspiriant LLC sold 340 Adobe shares in Q1 2026, an estimated $94.2K.
  • Adobe made up 0.08% of Aspiriant LLC's portfolio in Q1 2026, its #90 holding.
  • Aspiriant LLC first reported a position in Adobe in Q1 2017 and has held it in 36 quarters since.
  • Aspiriant LLC's Adobe position peaked at $4.33M in Q4 2025.
  • 2,178 funds tracked by Wall St. Rank held Adobe as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.